Valneva SE
VALN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001836564
No open-market purchases or sales by Valneva SE insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $19.8M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Valneva SE changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 11 | 9 | −2 |
| Shares | 137.9K | 61.9K | −75.9K (−55.1%) |
| Value | $4.70M | $1.40M | −$3.30M (−70.2%) |
New holders (3)
Institutions that held Valneva SE at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 1,372 | $31.0K | 0.00% |
| Advisor Group Holdings, Inc. | 1,450 | $30.0K | 0.00% |
| Royal Bank of Canada | 44 | $1.00K | 0.00% |
Sold out (5)
Institutions that held Valneva SE at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Alps Advisors Inc | 53,901 | $1.83M |
| Jane Street Group, LLC | 16,584 | $569.0K |
| Wells Fargo & Company | 4,238 | $145.0K |
| Tower Research Capital LLC (TRC) | 1,312 | $45.0K |
| Steward Partners Investment Advisory, LLC | 570 | $20.0K |